Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Assessing Effectiveness of Adding Niosomal Atorvastatin 1% Ointment to Topical Calcineurin Inhibitor Treatment in Non-Segmental Vitiligo Publisher Pubmed



Zartab H1, 2 ; Aflatoonian M3 ; Shamsimeymandi S4 ; Pardakhty A5 ; Isazadeh A6 ; Firooz A1 ; Amiri R7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Taleghani Hospital, Urmia University of Medical Sciences, Urmia, Iran
  3. 3. Afzalipour Hospital, Kerman University of Medical Sciences, Kerman, Iran
  4. 4. Pathology and Stem Cells Research Center, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
  5. 5. Neuropharmacology Institute, Pharmaceutics Research Center, Kerman University of Medical Sciences, Kerman, Iran
  6. 6. Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran
  7. 7. Leishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran

Source: Journal of Cosmetic Dermatology Published:2024


Abstract

Background: Treatment of vitiligo is still a big challenge for dermatologists. The efficacy of statins in the treatment of vitiligo is controversial. Aim and Objective: We studied possible therapeutic effect of topical 1% niosomal atorvastatin ointment combined with topical 0.1% tacrolimus in treatment of non-segmental vitiligo. Methods: This is a triple blind, pilot, randomized placebo-controlled trial (RCT) that was performed in dermatology clinic. All the patients used topical 0.1% tacrolimus cream twice daily (BD). Moreover, the intervention group participants used topical 1% niosomal atorvastatin ointment, and control group participants were prescribed placebo ointment, BD. Patients were evaluated using vitiligo area surface index (VASI) score and patients' satisfaction at baseline and after 3 months treatment. Results: The mean patient satisfaction in the intervention and control groups were 5 ± 1.4 and 3.5 ± 1.9; the difference between groups was not statistically significant (p = 0.9). We found statistically significant difference in VASI score before and after treatment in both intervention and control groups (p = 0.01 and p = 0.03, respectively). However, comparison of the VASI score between groups was not statistically significant (p = 0.62). We also found no significant correlation between VASI score and other variables. Conclusion: The result of this study indicates that adding of niosomal atorvastatin 1% ointment to topical calcineurin inhibitor has no additional effect on non-segmental type of vitiligo. Further large studies with different combinations are recommended before any conclusive result can be concluded on efficacy of statins in vitiligo. © 2024 The Authors. Journal of Cosmetic Dermatology published by Wiley Periodicals LLC.
Related Docs
1. Vitiligo Pathogenesis and Emerging Treatments, Dermatologic Clinics (2017)